NICE rejects promising oncology agents once again, citing high drug cost.
Two drugs that have offered hope to advanced breast cancer and advanced non-small cell lung cancer (NSCLC) patient have been rejected by the advisory watchdog to UK’s National Health Service, the National Institute for Health and Care Excellence. Nivolumab (Opdivo), manufactured by Bristol-Myers Squibb, and trastuzumab emtansine (Kadcyla), manufactured by Roche, have both received a thumbs down by NICE.
In a draft guidance, NICE said that that using nivolumab as second-line treatment following chemotherapy in NSCLC patients was not a cost-effective option for the healthcare system in England. Reacting to this recommendation by NICE, Paul Workman, PhD, who leads the Institute of Cancer Research urged the pharmaceutical industry to reconsider the cost equation for promising drugs such as the new class of immunotherapy agents. “There is no question that this pioneering and innovative treatment improves and extends the life of patients with non-small cell lung cancer — a disease that has very limited treatment options – but at this price it is very clearly too expensive,” Workman said.
A similar fate was established for trastuzumab emtansine. According to NICE, £90,000 is too expensive for NHS to pay for treating a single advanced breast cancer patient. This, despite Roche offering a discounted price on the drug.
Males With Hemophilia A Report Physical, Mental Burdens of Disease Regardless of Severity
April 25th 2024Self-reported data from adult and pediatric males with hemophilia A show that burden of the disease persists regardless of severity, highlighting a need for improved prophylactic treatment.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
What We’re Reading: FDA Approves UTI Antibiotic; Ozempic, Wegovy Price Investigation; US Births Fall
April 25th 2024The FDA recently approved an antibiotic for the treatment of urinary tract infections (UTIs) in women; a Senate committee recently launched an investigation into the prices of Novo Nordisk’s diabetes and weight loss drugs; US births fell last year, resuming a national slide after a previous increase during the pandemic.
Read More